Bilastine Safety in Lactating Mothers
Based on available evidence, bilastine lacks specific human lactation data and should be used with caution during breastfeeding, though general antihistamine safety data suggests it is likely compatible.
Evidence Assessment
Direct Evidence on Bilastine and Lactation
The provided evidence contains no specific human data on bilastine excretion into breast milk or effects on breastfed infants. The FDA drug label 1 does not address lactation safety, and none of the clinical studies 2, 3, 4, 5, 6, 7, 8 evaluated bilastine use during breastfeeding.
General Antihistamine Safety During Breastfeeding
All antihistamines are considered safe during breastfeeding according to published literature, as minimal amounts are excreted in breast milk and would not cause adverse effects in breastfeeding infants 9. This applies to both first-generation sedating antihistamines and second-generation non-sedating agents, though data on newer agents are more limited 9.
Pharmacological Considerations Supporting Safety
Bilastine has several properties that theoretically support its safety during lactation:
- No hepatic metabolism: Bilastine does not undergo significant metabolism and does not interact with the CYP450 system 2, 5, reducing potential for accumulation
- Highly selective H1 receptor binding: No affinity for other receptors 2, 3
- No CNS penetration: The drug shows no central nervous system penetration 2, suggesting limited ability to cross biological membranes
- Rapid elimination: Quick absorption and clearance profile 2
- No sedative effects: Minimal sedative properties even at above-standard doses 5
Clinical Recommendation
If bilastine is clinically indicated for a lactating mother:
- Consider it likely compatible with breastfeeding based on the general safety profile of second-generation antihistamines 9
- Use the standard 20 mg once-daily dose (no dose adjustment needed) 5
- Take bilastine at least 1 hour before or 2 hours after meals to optimize absorption 4
- Monitor the infant for unusual drowsiness, irritability, or feeding difficulties (though unlikely given the drug's non-sedating profile)
Alternative Considerations
If absolute certainty about lactation safety is required, consider antihistamines with established human lactation data, such as cetirizine or lorazepam, which have been more extensively studied in breastfeeding populations.
Important Caveats
- The absence of reported adverse effects does not equal proven safety—it reflects lack of systematic study
- Bilastine's large molecular structure and lack of CNS penetration suggest minimal milk transfer, but this has not been quantified in humans
- The drug's excellent safety profile in children as young as 2 years 8 provides indirect reassurance about infant exposure